Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 24:13:932154.
doi: 10.3389/fphar.2022.932154. eCollection 2022.

Recent findings in the regulation of G6PD and its role in diseases

Qingfei Meng  1 , Yanghe Zhang  1 , Shiming Hao  1 , Huihui Sun  1 , Bin Liu  2 , Honglan Zhou  2 , Yishu Wang  1 , Zhi-Xiang Xu  1   2   3
Affiliations
Review

Recent findings in the regulation of G6PD and its role in diseases

Qingfei Meng et al. Front Pharmacol. .

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) is the only rate-limiting enzyme in the pentose phosphate pathway (PPP). Rapidly proliferating cells require metabolites from PPP to synthesize ribonucleotides and maintain intracellular redox homeostasis. G6PD expression can be abnormally elevated in a variety of cancers. In addition, G6PD may act as a regulator of viral replication and vascular smooth muscle function. Therefore, G6PD-mediated activation of PPP may promote tumor and non-neoplastic disease progression. Recently, studies have identified post-translational modifications (PTMs) as an important mechanism for regulating G6PD function. Here, we provide a comprehensive review of various PTMs (e.g., phosphorylation, acetylation, glycosylation, ubiquitination, and glutarylation), which are identified in the regulation of G6PD structure, expression and enzymatic activity. In addition, we review signaling pathways that regulate G6PD and evaluate the role of oncogenic signals that lead to the reprogramming of PPP in tumor and non-neoplastic diseases as well as summarize the inhibitors that target G6PD.

Keywords: glucose-6-phosphate dehydrogenase; metabolic reprogramming; pentose phosphate pathway; post-translational modifications; tumorigenesis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Transcriptional regulation of G6PD. The cartoon diagram on display consists of three main parts. On the left, activation of NF-ĸB in response to cellular stresses or the PIEKA-FYN complex leads to the phosphorylation and activation of STAT3, which results in the translocation of p-STAT3 to the nucleus and binding to the G6PD promoter enhancing transcription. In the middle section, signals regulate the expression of HMGA1 to promote G6PD transcription. On the right side, HBV protein forms a complex with intracellular protein p62 and KEAP1, resulting in translocation of NRF2 into the nucleus to promote G6PD expression. At the bottom, methylation and acetylation of histones are involved in transcriptional regulation of G6PD.
FIGURE 2
FIGURE 2
G6PD post-translational modifications. Phosphorylation, glycosylation, acetylation and glutarylation modifications regulate G6PD enzyme activity and specific sites identified are shown in the central circle. Ubiquitination and SUMOylation are synergistically involved in the regulation of G6PD protein stability. Acetylation and methylation of histones H3K27 and H3K9 regulate G6PD transcriptional expression, respectively.
FIGURE 3
FIGURE 3
Schematic diagram of G6PD (PDB: 2BH9) dimer. A dimer consisting of two G6PD monomers, each of which includes a catalytic NADP+ and structural NADP+, respectively. The G6PD K403, Y401 and T406 sites are located close to the structural NADP+.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ai G., Dachineni R., Kumar D. R., Alfonso L. F., Marimuthu S., Bhat G. J. (2016). Aspirin inhibits glucose6phosphate dehydrogenase activity in HCT 116 cells through acetylation: Identification of aspirin-acetylated sites. Mol. Med. Rep. 14 (2), 1726–1732. 10.3892/mmr.2016.5449 - DOI - PMC - PubMed
    1. Ata H., Rawat D. K., Lincoln T., Gupte S. A. (2011). Mechanism of glucose-6-phosphate dehydrogenase-mediated regulation of coronary artery contractility. Am. J. Physiol. Heart Circ. Physiol. 300 (6), H2054–H2063. 10.1152/ajpheart.01155.2010 - DOI - PMC - PubMed
    1. Au S. W., Gover S., Lam V. M., Adams M. J. (2000). Human glucose-6-phosphate dehydrogenase: The crystal structure reveals a structural NADP(+) molecule and provides insights into enzyme deficiency. Structure 8 (3), 293–303. 10.1016/s0969-2126(00)00104-0 - DOI - PubMed
    1. Au S. W., Naylor C. E., Gover S., Vandeputte-Rutten L., Scopes D. A., Mason P. J., et al. (1999). Solution of the structure of tetrameric human glucose 6-phosphate dehydrogenase by molecular replacement. Acta Crystallogr. D. Biol. Crystallogr. 55 (4), 826–834. 10.1107/s0907444999000827 - DOI - PubMed
    1. Aurora A. B., Khivansara V., Leach A., Gill J. G., Martin-Sandoval M., Yang C., et al. (2022). Loss of glucose 6-phosphate dehydrogenase function increases oxidative stress and glutaminolysis in metastasizing melanoma cells. Proc. Natl. Acad. Sci. U. S. A. 119 (6), e2120617119. 10.1073/pnas.2120617119 - DOI - PMC - PubMed